VALENCIA, CA -- Bioness, Inc. announces its StimRouter Neuromodulation System has been chosen as a 2016 Medical Device Excellence Awards (MDEA) finalist. MDEA is a worldwide competition that recognizes products that are commercially available and approved as a medical device either by the U.S. FDA or other relevant notified body.
The 2016 MDEA competition includes ten different product categories that represent instruments, machines, implants, in vitro reagents, mobile medical applications, or other related products. StimRouter was selected as a finalist in the Implant and Tissue-Replacement Products category.
The StimRouter System is an implantable device designed to deliver safe, effective long-term chronic pain relief, easily controlled by the patient, at home or on-the-go. StimRouter precisely delivers stimulation to the exact nerve causing the pain but without a large implanted pulse generator or battery, so the device minimizes tissue trauma and infection incidence while reducing recovery time.
Entries will be judged in five critical categories: design and engineering innovations, functional (user-related) innovations, benefit to overall healthcare, benefit to patients and market differentiation. Winners will be announced June 14, 2016 during a special ceremony at the Medical Device and Manufacturing (MD&M) East Conference and Exposition in New York City.
About StimRouter Neuromodulation System
The StimRouter™ Neuromodulation System is intended to provide electrical stimulation via a small implanted lead to a target peripheral nerve, for the management of severe intractable chronic pain of peripheral nerve origin in adults, as an adjunct to other modes of therapy.
StimRouter is a minimally invasive procedure consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, handheld wireless patient programmer. StimRouter is programmed at the direction of the physician to meet unique pain management requirements.